Last updated: 2026-09-22 11:54:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Vera Therapeutics, Inc. (VERA) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $34.54, with a market capitalization of $2.45B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $23.05 to $56.05. This page covers its latest market performance, valuation, price trends and company information.
$2.45B | |
$34.23 | |
$56.05 | |
$5.20 | |
$34.25 | |
4.44K | |
2.47M | |
-- | |
$56.05 | |
$23.05 | |
-- | |
-- |
Vera Therapeutics, Inc. (VERA) is trading at $34.54 in pre-market trading as of 2026-09-22 11:36:00, up 0.85% ($0.29) from the previous close of $34.25
Pre-market trading shows how investors are pricing VERA before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Vera Therapeutics, Inc. (VERA) moved from $35.05 to $34.54, representing a decline of 1.46% ($0.51).
The stock traded between $31.19 and $37.14 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 4.17 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 34.8%
VERA is currently trading at $34.54, placing it 34.8% of the way from its 52-week low of $23.05 to its 52-week high of $56.05. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 361 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Vera Therapeutics, Inc. (VERA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.